Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital lifts Standard Chartered estimates, but shares 'up with events'

(Sharecast News) - Shore Capital has raised its numbers for Standard Chartered after the bank's stronger-than-expected second-quarter results, but kept a 'hold' rating on the stock despite the company's increasing momentum. The broker upped its fair value estimate for the shares from 1,270p to 1,355p, but said the stock looks "up with events", following a 38% surge so far this year and an 88% jump over the past 12 months.

Thursday's update from the emerging markets lender showed pre-tax profits at $2.28bn, up 44% over last year and some 32% ahead of consensus forecasts.

Even after adjusting for a one-off $238m gain on the disposal of ecommerce marketplace Solv India that wasn't fully captured into market estimates, the company still impressed with income generation, and lower impairment and restructuring charges than expected.

"This strong momentum is said to have continued into Q3, resulting in an FY25F income guidance upgrade, which is reflected in our revised estimates. Whether it can be sustained into Q4 and beyond is more questionable," Shore Capital said.

The company, which has benefitted from the increased volatility caused by US tariff uncertainty, may find that income growth could be limited next year if volatility normalises, especially given the strong comparative with this year, the broker said.

"Following a strong run, the shares are trading in line with our revised fair value of 1,355p," Shore Capital said.

The stock was down 0.4% at 1,354.5p on Friday afternoon, trading more or less in line with the Shore Capital's estimate.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.